Learn Before
Relation
Severe COVID-19 cases and the impact of tocilizumab
- Patients with severe cases of COVID-19 were given tocilizumab
- Tocilizumab lowered the patients’ body temperature, this returning the fever to normal (after 1 day)
- 15/20 patients required less oxygen therapy (after 5 days)
- The lymphocyte count (in peripheral blood) in about half the patients returned to the normal range
- Lowered C-reactive protein to a safe level in 16/19 patients
- All the patients were discharged after approximately 15 days
0
0
Updated 2020-08-05
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Outcomes among 100 severe COVID-19 patients in Brescia, Italy during 10-day follow-up after Tocilizumab (TCZ) infusion
Figure illustrating how Tocilizumab calms the inflammatory storm by blocking IL-6 receptors
Severe COVID-19 cases and the impact of tocilizumab
Toxicities of TCZ
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
Case Report of Tocilizumab for COVID-19 Pneumonia in a Non Small Cell Lung Cancer Patient Treated with Chemo-Immunotherapy
Treatment with Tocilizumab or Corticosteroids for COVID-19 Patients with Hyperinflammatory State